Publications by authors named "J A Ledermann"

Claim this Profile
M
Mechanisms of drug resistance: PARP inhibitors, antibody-drug-conjugates, and immunotherapy.
Diana Bello Roufai, Richard Toth, Upasana Palo, Giula Scaglione, Ana Tatiana Palacios, Jonathan Ledermann

Int J Gynecol Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The PARP inhibitor/Immunotherapy Paradox in Advanced Ovarian Cancer: Positive Endpoints, Perplexing Interpretations.
Jonathan A Ledermann, Robert L Coleman

Ann Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PARP Inhibitor Maintenance After First-Line Chemotherapy in Advanced-Stage Epithelial Ovarian Cancer: A Systematic Review and Meta-Analysis.
Stamatios Petousis, Ilker Kahramanoglu, Christian Appenzeller-Herzog, Martina A Angeles, Chrysoula Margioula-Siarkou, Jonathan A Ledermann

JAMA Netw Open· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
ESGO-ESTRO-ESP guidelines for the management of patients with endometrial carcinoma: update 2025.
Nicole Concin, Xavier Matias-Guiu, David Cibula, Nicoletta Colombo, Carien L Creutzberg, Jonathan Ledermann

Lancet Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
INTERLACE: not a new standard for cervical cancer chemoradiation - Authors' reply.
Mary McCormack, Gemma Eminowicz, Simran Vaja, Allan Hackshaw, Jonathan Ledermann

Lancet· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis